Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Carcinoma, Hepatocellular 5Leukemia, Myeloid, Acute 3Uveal Melanoma 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leiomyosarcoma 1HER2 Negative Metastatic Breast Cancer 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1Advanced Pancreatic Cancer 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × ADI PEG20 × Clear all
NCT05001828 2026-01-21

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Polaris Group

Phase 1 Active not recruiting
38 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01910012 2020-10-01

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

Polaris Group

Phase 2 Completed
43 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02875093 2020-03-05

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Polaris Group

Phase 1 Terminated
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡